Moleculin Announces Completion Of Enrollment In U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin For The Treatment Of Soft Tissue Sarcoma Lung Metastases
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech has completed enrollment for its U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. Preliminary data shows over 60% of subjects exhibited stable disease after two treatment cycles. Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA. Data readouts are expected before the end of the year.
September 21, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moleculin's completion of enrollment for its Phase 1B/2 clinical trial of Annamycin could potentially boost investor confidence. The preliminary efficacy data and FDA designations may also positively impact the stock.
The completion of enrollment indicates progress in Moleculin's clinical trial, which could boost investor confidence. The preliminary efficacy data showing over 60% of subjects exhibiting stable disease is a positive sign. Additionally, the FDA's Fast Track Status and Orphan Drug Designation for Annamycin could potentially expedite the drug's approval process, which would be beneficial for the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100